COMP <GO>
PAHC vs ETON // EV/EBITDA & P/E VALUATION
Phibro Animal Health Corporation (Class A) (NASDAQ) VS. Eton Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: PAHC 8
— ETON 3
■ METRIC PARITY
LAST: $38.86 (+2.59%) • MKT CAP: $1.58B
valuation
19.2x
LAST: $53.67 (+3.61%) • MKT CAP: $1.53B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PAHC VS. ETON)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PAHC | ETON | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 30.90% | 53.50% | -22.60 | ETON | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | -0.90% | +10.80 | PAHC | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.2x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.08% | 0.66% | +4.42 | PAHC | /fcf-yield <GO> |
| Operating Margin | 8.50% | -1.10% | +9.60 | PAHC | /operating-margins <GO> |
| Net Profit Margin | 3.70% | -5.80% | +9.50 | PAHC | /net-margins <GO> |
| Revenue Growth (YoY) | 27.40% | 104.90% | -77.50 | ETON | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.23% | 0.00% | +1.23 | PAHC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.87 | 13.37 | -10.50 | ETON | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | PAHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 47.9 | +9.01 | PAHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.5x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.58B | $1.53B | $43.7M | PAHC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PAHC REV | ETON REV | PAHC GROSS % | ETON GROSS % | PAHC FCF | ETON FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.30B | $80.0M | 30.9% | 53.5% | $80.1M | $10.2M |
| FY 2024 | $1.02B | $39.0M | 30.8% | 60.0% | $87.6M | $943.0K |
| FY 2023 | $977.9M | $31.6M | — | — | $13.3M | $6.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PAHC // BETA —
ETON // BETA —